Overview Dividends

(EW) Edwards Lifesciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

Heart Valves, Surgical Solutions, Transcatheter Products, Cardiovascular Devices

EW EPS (Earnings per Share)

EPS (Earnings per Share) of EW over the last years for every Quarter: "2020-09-30": 0.51, "2020-12-31": 0.5, "2021-03-31": 0.54, "2021-06-30": 0.64, "2021-09-30": 0.54, "2021-12-31": 0.51, "2022-03-31": 0.6, "2022-06-30": 0.63, "2022-09-30": 0.61, "2022-12-31": 0.64, "2023-03-31": 0.62, "2023-06-30": 0.66, "2023-09-30": 0.59, "2023-12-31": 0.64, "2024-03-31": 0.66, "2024-06-30": 0.7, "2024-09-30": 0.67, "2024-12-31": 0.59, "2025-03-31": 0.64, "2025-06-30": 0.67,
EPS Growth (3Y CAGR): 3.47%
EPS Trend (3Y Correlation): 31.1%

EW Revenue

Revenue of EW over the last years for every Quarter: 2020-09-30: 1140.9, 2020-12-31: 1191.7, 2021-03-31: 1216.6, 2021-06-30: 1376, 2021-09-30: 1310.2, 2021-12-31: 1329.7, 2022-03-31: 1341.2, 2022-06-30: 1373.9, 2022-09-30: 1319, 2022-12-31: 1348.3, 2023-03-31: 1459.6, 2023-06-30: 1295.5, 2023-09-30: 1243.4, 2023-12-31: 1266.4, 2024-03-31: 1329.9, 2024-06-30: 1385.9, 2024-09-30: 1354.4, 2024-12-31: 1385.8, 2025-03-31: 1412.7, 2025-06-30: 1532.2,
Revenue Growth (3Y CAGR): 5.60%
Revenue Trend (3Y Correlation): 49.1%

Description: EW Edwards Lifesciences

Edwards Lifesciences Corp (NYSE:EW) is a leading provider of innovative cardiovascular disease treatments, offering a range of products for transcatheter heart valve replacement and repair, as well as surgical structural heart solutions. The companys product portfolio includes the Edwards SAPIEN family of valves, PASCAL PRECISION, and Cardioband, among others.

Key performance indicators (KPIs) for Edwards Lifesciences include revenue growth, driven by increasing adoption of its transcatheter heart valve replacement products, and expanding margins due to operational efficiencies. The companys return on equity (RoE) of 45.06% indicates strong profitability. Additionally, Edwards Lifesciences dividend yield and payout ratio can be evaluated to assess its commitment to returning capital to shareholders.

From a competitive landscape perspective, Edwards Lifesciences operates in the health care equipment industry, where it competes with companies such as Medtronic and Abbott Laboratories. The companys market share and competitive positioning can be assessed by analyzing its product offerings, sales force effectiveness, and distribution network.

To further evaluate Edwards Lifesciences investment potential, metrics such as EV/EBITDA, debt-to-equity ratio, and interest coverage ratio can be examined to gauge its financial health and leverage. Furthermore, the companys research and development (R&D) expenses as a percentage of revenue can be analyzed to assess its commitment to innovation and new product development.

EW Stock Overview

Market Cap in USD 47,532m
Sub-Industry Health Care Equipment
IPO / Inception 2000-03-27

EW Stock Ratings

Growth Rating 9.09%
Fundamental 76.3%
Dividend Rating -
Return 12m vs S&P 500 -5.63%
Analyst Rating 3.69 of 5

EW Dividends

Currently no dividends paid

EW Growth Ratios

Growth Correlation 3m 48.8%
Growth Correlation 12m 84.2%
Growth Correlation 5y -59.9%
CAGR 5y -4.12%
CAGR/Max DD 3y -0.11
CAGR/Mean DD 3y -0.23
Sharpe Ratio 12m -0.88
Alpha 0.12
Beta 0.600
Volatility 27.33%
Current Volume 4844.9k
Average Volume 20d 3734.3k
Stop Loss 72.9 (-3.1%)
Signal -0.52

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (4.14b TTM) > 0 and > 6% of Revenue (6% = 341.1m TTM)
FCFTA 0.07 (>2.0%) and ΔFCFTA 2.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 90.98% (prev 63.13%; Δ 27.85pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.09 (>3.0%) and CFO 1.20b <= Net Income 4.14b (YES >=105%, WARN >=100%)
Net Debt (-2.57b) to EBITDA (1.78b) ratio: -1.44 <= 3.0 (WARN <= 3.5)
Current Ratio 4.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (587.9m) change vs 12m ago -2.71% (target <= -2.0% for YES)
Gross Margin 78.90% (prev 78.75%; Δ 0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 48.20% (prev 51.74%; Δ -3.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 82.39 (EBITDA TTM 1.78b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3)

Altman Z'' 11.99

(A) 0.38 = (Total Current Assets 6.58b - Total Current Liabilities 1.40b) / Total Assets 13.49b
(B) 1.03 = Retained Earnings (Balance) 13.86b / Total Assets 13.49b
warn (B) unusual magnitude: 1.03 — check mapping/units
(C) 0.14 = EBIT TTM 1.63b / Avg Total Assets 11.79b
(D) 4.94 = Book Value of Equity 14.25b / Total Liabilities 2.88b
Total Rating: 11.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.30

1. Piotroski 6.0pt = 1.0
2. FCF Yield 2.29% = 1.14
3. FCF Margin 17.76% = 4.44
4. Debt/Equity 0.06 = 2.50
5. Debt/Ebitda 0.35 = 2.41
6. ROIC - WACC (= 5.66)% = 7.07
7. RoE 41.22% = 2.50
8. Rev. Trend 49.13% = 3.68
9. EPS Trend 31.13% = 1.56

What is the price of EW shares?

As of September 18, 2025, the stock is trading at USD 75.20 with a total of 4,844,927 shares traded.
Over the past week, the price has changed by -3.93%, over one month by -3.96%, over three months by +2.63% and over the past year by +11.85%.

Is Edwards Lifesciences a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 76.30 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 69.55 USD . This means that EW is currently overvalued and has a potential downside of -7.51%.

Is EW a buy, sell or hold?

Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.
  • Strong Buy: 10
  • Buy: 4
  • Hold: 17
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the EW price?

Issuer Target Up/Down from current
Wallstreet Target Price 87.7 16.7%
Analysts Target Price 87.7 16.7%
ValueRay Target Price 77.3 2.8%

Last update: 2025-09-05 04:42

EW Fundamental Data Overview

Market Cap USD = 47.53b (47.53b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 4.06b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.8745
P/E Forward = 29.4985
P/S = 8.3607
P/B = 4.5219
P/EG = 4.3755
Beta = 1.07
Revenue TTM = 5.69b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.78b USD
Long Term Debt = 598.0m USD (from longTermDebt, last quarter)
Short Term Debt = 25.9m USD (from shortTermDebt, last quarter)
Debt = 623.9m USD (Calculated: Short Term 25.9m + Long Term 598.0m)
Net Debt = -2.57b USD (from netDebt column, last quarter)
Enterprise Value = 44.09b USD (47.53b + Debt 623.9m - CCE 4.06b)
Interest Coverage Ratio = 82.39 (Ebit TTM 1.63b / Interest Expense TTM 19.8m)
FCF Yield = 2.29% (FCF TTM 1.01b / Enterprise Value 44.09b)
FCF Margin = 17.76% (FCF TTM 1.01b / Revenue TTM 5.69b)
Net Margin = 72.90% (Net Income TTM 4.14b / Revenue TTM 5.69b)
Gross Margin = 78.90% ((Revenue TTM 5.69b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Tobins Q-Ratio = 3.09 (Enterprise Value 44.09b / Book Value Of Equity 14.25b)
Interest Expense / Debt = 3.17% (Interest Expense 19.8m / Debt 623.9m)
Taxrate = 9.82% (152.1m / 1.55b)
NOPAT = 1.47b (EBIT 1.63b * (1 - 9.82%))
Current Ratio = 4.68 (Total Current Assets 6.58b / Total Current Liabilities 1.40b)
Debt / Equity = 0.06 (Debt 623.9m / last Quarter total Stockholder Equity 10.55b)
Debt / EBITDA = 0.35 (Net Debt -2.57b / EBITDA 1.78b)
Debt / FCF = 0.62 (Debt 623.9m / FCF TTM 1.01b)
Total Stockholder Equity = 10.05b (last 4 quarters mean)
RoA = 30.72% (Net Income 4.14b, Total Assets 13.49b )
RoE = 41.22% (Net Income TTM 4.14b / Total Stockholder Equity 10.05b)
RoCE = 15.31% (Ebit 1.63b / (Equity 10.05b + L.T.Debt 598.0m))
RoIC = 13.81% (NOPAT 1.47b / Invested Capital 10.65b)
WACC = 8.15% (E(47.53b)/V(48.16b) * Re(8.22%)) + (D(623.9m)/V(48.16b) * Rd(3.17%) * (1-Tc(0.10)))
Shares Correlation 3-Years: -93.94 | Cagr: -0.55%
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 72.83% ; FCFE base≈821.2m ; Y1≈623.1m ; Y5≈380.6m
Fair Price DCF = 11.83 (DCF Value 6.95b / Shares Outstanding 587.1m; 5y FCF grow -28.62% → 3.0% )
EPS Correlation: 31.13 | EPS CAGR: 3.47% | SUE: 2.83 | # QB: 4
Revenue Correlation: 49.13 | Revenue CAGR: 5.60% | SUE: N/A | # QB: None

Additional Sources for EW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle